Animal Models of Transplantable Bladder Cancer: A Review
Bladder cancer (BC) is one of the most common cancers worldwide. At present, numerous treatments of BC are available, but the response to treatment varies from patient to patient. Hence, there is a need to re-explore the mechanisms and biology of BC development and develop robust and effective therapies against BC. Animal models are the powerful tools which have been and are still used in studies that link the knowledge gap between fundamental and clinical research. Animal models of transplantable BC is the most frequently used animal models that are established by transplanting BC cell lines or BC tissues into the animal to form a tumor. Recapitulation of human cancer condition in these animal models enables the scientists to further explore BC development, progression, and metastasis. In addition, the use of animal models of transplantable BC facilitates the identification of drug targets that are the primary part of an attempt to reverse therapeutic resistance and improve clinical outcomes. Overall, animal models present themselves as critical tools which help address the complex issues in BC research. This review summarizes the classification of animal models of transplantable BC, discusses advanced methods of establishing and monitoring tumor models, and compares the advantages and disadvantages of each establishment method.
Bray F, Ferlay J, Soerjomataram I, et al., 2018, Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 68:394–424. DOI: 10.3322/caac.21492.
Spiess PE, Czerniak B, 2006, Dual-track Pathway of Bladder Carcinogenesis: Practical Implications. Arch Pathol Lab Med, 130:844–52.
Czerniak B, Dinney C, McConkey D, 2016, Origins of Bladder Cancer. Annu Rev Pathol, 11:149–74. DOI: 10.1146/annurev-pathol-012513-104703.
DeGeorge KC, Holt HR, Hodges SC, 2017, Bladder Cancer: Diagnosis and Treatment. Am Fam Physician, 96:507–14.
Cheon DJ, Orsulic S, 2011, Mouse Models of Cancer. Annu Rev Pathol, 6:95–119.
Olson B, Li Y, Lin Y, et al., 2018, Mouse Models for Cancer Immunotherapy Research. Cancer Discov, 8:1358–65.
Gengenbacher N, Singhal M, Augustin HG, 2017, Preclinical Mouse Solid Tumour Models: Status Quo, Challenges and Perspectives. Nat Rev Cancer, 17:751–65. DOI: 10.1038/nrc.2017.92.
Okada S, Vaeteewoottacharn K, Kariya R, 2019, Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models. Cells, 8:889. DOI: 10.3390/cells8080889.
Weldon TE, Soloway MS, 1975, Susceptibility of Urothelium to Neoplastic Cellular Implantation. Urology, 5:824–7. DOI: 10.1016/0090-4295(75)90367-2.
Ireson CR, Alavijeh MS, Palmer AM, et al., 2019, The Role of Mouse Tumour Models in the Discovery and Development of Anticancer Drugs. Br J Cancer, 121:101–8. DOI: 10.1038/s41416-019-0495-5.
Bosma GC, Custer RP, Bosma MJ, 1983, A Severe Combined Immunodeficiency Mutation in the Mouse. Nature, 301:527–30. DOI: 10.1038/301527a0.
Belizario JE, 2009, Immunodeficient Mouse Models: An Overview. Open Immunol J, 2:79–85.
Katano I, Ito R, Eto T, et al., 2011, Immunodeficient NOD-scid IL-2Rgnull Mice Do Not Display T and B Cell Leakiness. Exp Anim, 60:181–6. DOI: 10.1538/expanim.60.181.
Medani S, O’Kelly P, O’Brien KM, et al., 2014, Bladder Cancer in Renal Allograft Recipients: Risk Factors and Outcomes. Transplant Proc, 46:3466–73. DOI: 10.1016/j.transproceed.2014.06.075.
Jankun J, Keck RW, Selman SH, 2014, Epigallocatechin-3-gallate Prevents Tumor Cell Implantation/Growth in an Experimental Rat Bladder Tumor Model. Int J Oncol, 44:147–52. Doi: 10.3892/ijo.2013.2174.
Dovedi SJ, Kirby JA, Davies BR, et al., 2008, Celecoxib Has Potent Antitumour Effects as a Single Agent and in Combination with BCG Immunotherapy in a Model of Urothelial Cell Carcinoma. Eur Urol, 54:621–30. DOI: 10.1016/j.eururo.2008.01.013.
Li CG, Li ML, Shu XH, et al., 2010, Antitumor Effects of Recombinant Human Interleukin-6 on Mouse Bladder Carcinoma through Fas-mediated Apoptosis. Cancer Chemother Pharmacol, 66:981–6. DOI: 10.1007/s00280-010-1336-7.
Sun E, Fan X, Wang L, et al., 2015, Recombinant hIFN-a2b-BCG inhibits Tumor Growth in a Mouse Model of Bladder Cancer. Oncol Rep, 34:183–94.
Smith SG, Koppolu BP, Ravindranathan S, et al., 2015, Intravesical Chitosan/Interleukin-12 Immunotherapy Induces Tumor-specific Systemic Immunity against Murine Bladder Cancer. Cancer Immunol Immunother, 64:689–196. DOI: 10.1007/s00262-015-1672-x.
Ruan JL, Hsu JW, Browning RJ, et al., 2019, Mouse Models of Muscle-invasive Bladder Cancer: Key Considerations for Clinical Translation Based on Molecular Subtypes. Eur Urol Oncol, 2:239–47. DOI: 10.1016/j.euo.2018.08.014.
Bernardo C, Costa C, Sousa N, et al., 2015, Patient-derived Bladder Cancer Xenografts: A Systematic Review. Transl Res, 166:324–31.
Zhao Q, Wang H, Yang M, et al., 2013, Expression of a Tumor-associated Gene, LASS2, in the Human Bladder Carcinoma Cell Lines BIU-87, T24, EJ and EJ-M3. Exp Ther Med, 5:942–6. DOI: 10.3892/etm.2013.892.
Choi SY, Kim SJ, Chi BH, et al., 2015, Modulating the Internalization of Bacille Calmette-Guerin by Cathelicidin in Bladder Cancer Cells. Urology, 85:964–7. DOI: 10.1016/j.urology.2014.12.028.
Sanchez-Carbayo M, Socci ND, Charytonowicz E, et al., 2002, Molecular Profiling of Bladder Cancer Using cDNA Microarrays: Defining Histogenesis and Biological Phenotypes. Cancer Res, 62:6973–80.
Kuwada M, Chihara Y, Luo Y, et al., 2015, Pro-chemotherapeutic Effects of Antibody Against Extracellular Domain of Claudin-4 in Bladder Cancer. Cancer Lett, 369:212–21. DOI: 10.1016/j.canlet.2015.08.019.
Cui M, Au JL, Wientjes MG, et al., 2015, Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts. J Urol, 194:230–7. DOI: 10.1158/1538-7445.am2014-2598.
Ding J, Xu D, Pan C, et al., 2014, Current Animal Models of Bladder Cancer: Awareness of Translatability (Review). Exp Ther Med, 8:691–9.
Kobayashi T, Owczarek TB, McKiernan JM, et al., 2015, Modelling Bladder Cancer in Mice: Opportunities and Challenges. Nat Rev Cancer, 15:42–54. DOI: 10.1038/nrc3858.
John BA, Said N, 2017, Insights from Animal Models of Bladder Cancer: Recent Advances, Challenges, and Opportunities. Oncotarget, 8:57766–81. DOI: 10.18632/oncotarget.17714.
Kang MR, Yang G, Charisse K, et al., 2012, An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment. J Vis Exp, 65:4207. DOI: 10.3791/4207.
Jäger W, Moskalev I, Janssen C, et al., 2014, Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts. J Vis Exp, e51123. DOI: 10.3791/51123.
George E, Kim H, Krepler C, et al., 2017, A Patient-derived-xenograft Platform to Study BRCA-deficient Ovarian Cancers. JCI Insight, 2:e89760.
Miyake M, Hori S, Morizawa Y, et al., 2016, CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. Neoplasia, 18:636–46. DOI: 10.1016/j.neo.2016.08.002.
Li Y, Cheng H, Xu W, et al., 2015, Expression of Robo Protein in Bladder Cancer Tissues and its Effect on the Growth of Cancer Cells by Blocking Robo Protein. Int J Clin Exp Pathol, 8:9932–40.
Hiles GL, Cates AL, El-Sawy L, et al., 2019, A Surgical Orthotopic Approach for Studying the Invasive Progression of Human Bladder Cancer. Nat Protoc, 14:738–55. DOI: 10.1038/s41596-018-0112-8.
Talmadge JE, Singh RK, Fidler IJ, et al., 2007, Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer. Am J Pathol, 170:793–804. DOI: 10.2353/ajpath.2007.060929.
Wu ML, Li H, Yu LJ, et al., 2014, Short-term Resveratrol Exposure Causes In Vitro and In Vivo Growth Inhibition and Apoptosis of Bladder Cancer Cells. PLoS One, 9:e89806. DOI: 10.1371/journal.pone.0089806.
Li C, Yang Z, Du Y, et al., 2014, BCMab1, a Monoclonal Antibody against Aberrantly Glycosylated Integrin a3b1, has Potent Antitumor Activity of Bladder Cancer In Vivo. Clin Cancer Res, 20:4001–13. DOI: 10.1158/1078-0432.ccr-13-3397.
Tao L, Qiu J, Jiang M, et al., 2016, Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1-->Androgen Receptor-->HIF1a-->VEGFa Signals. Mol Cancer Ther, 15:1943–51. DOI: 10.1158/1535-7163.mct-15-0306.
Cirone P, Andresen CJ, Eswaraka JR, et al., 2014, Patient-derived Xenografts Reveal Limits to PI3K/mTOR- and MEK-mediated Inhibition of Bladder Cancer. Cancer Chemother Pharmacol, 73:525–38. DOI: 10.1007/s00280-014-2376-1.
Black PC, Dinney CP, 2007, Bladder Cancer Angiogenesis and Metastasis--translation from Murine Model to Clinical Trial. Cancer Metastasis Rev, 26:623–34. DOI: 10.1007/s10555-007-9084-9.
Park B, Jeong BC, Choi YL, et al., 2013, Development and Characterization of a Bladder Cancer Xenograft Model Using Patient-derived Tumor Tissue. Cancer Sci 104:631–8. DOI: 10.1111/cas.12123.
Murayama T, Gotoh N, 2019, Patient-Derived Xenograft Models of Breast Cancer and Their Application. Cells, 8:621. DOI: 10.3390/cells8060621.
Gong Z, Xu H, Su Y, et al., 2015, Establishment of a Novel Bladder Cancer Xenograft Model in Humanized Immunodeficient Mice. Cell Physiol Biochem, 37L1355–68.
Rossetti T, Nicholls F, Modo M, 2016, Intracerebral Cell Implantation: Preparation and Characterization of Cell Suspensions. Cell Transplant, 25:645–64. DOI: 10.3727/096368915x690350
Kolawole OM, Lau WM, Mostafid H, et al., 2017, Advances in Intravesical Drug Delivery Systems to Treat Bladder Cancer. Int J Pharm, 532:105–17. DOI: 10.1016/j.ijpharm.2017.08.120.
Patel AR, Chan ES, Hansel DE, et al., 2010, Transabdominal Micro-ultrasound Imaging of Bladder Cancer in a Mouse Model: A Validation Study. Urology, 75:799–804. DOI: 10.1016/j.urology.2009.06.047.
Lee JS, Bae MH, Choi SH, et al., 2012, Tumor Establishment Features of Orthotopic Murine Bladder Cancer Models. Korean J Urol, 53:396–400.
Kasman L, Voelkel-Johnson C, 2013, An Orthotopic Bladder Cancer Model for Gene Delivery Studies. J Vis Exp, 82:50181. DOI: 10.3791/50181.
Gardin JM, Siri F, Kitsis RN, et al., 1996, Intravascular Ultrasound Catheter Evaluation of the Left Ventricle in Mice: A Feasibility Study. Echocardiography, 13:609–12. DOI: 10.1111/j.1540-8175.1996.tb00941.x.
Satoh H, Morimoto Y, Arai T, et al., 2007, Intravesical Ultrasonography for Tumor Staging in an Orthotopically Implanted Rat Model of Bladder Cancer. J Urol, 177:1169–73. DOI: 10.1016/j.juro.2006.10.038.
Wallace MB, Meining A, Canto MI, et al., 2010, The Safety of Intravenous Fluorescein for Confocal Laser Endomicroscopy in the Gastrointestinal Tract. Aliment Pharmacol Ther, 31:548–52. DOI: 10.1111/j.1365-2036.2009.04207.x.
Sonn GA, Jones SN, Tarin TV, et al., 2009, Optical Biopsy of Human Bladder Neoplasia with In Vivo Confocal Laser Endomicroscopy. J Urol, 182:1299–305. DOI: 10.1016/j.juro.2009.06.039.
Fazel J, Rötzer S, Seidl C, et al., 2015, Fractionated Intravesical Radioimmunotherapy with (213)Bi-anti-EGFR-MAb is Effective without Toxic Side-effects in a Nude Mouse Model of Advanced Human Bladder Carcinoma. Cancer Biol Ther, 16:1526–34. DOI: 10.1080/15384047.2015.1071735.
Yang D, Wang H, Wang J, et al., 2011, Establishment of a Fluorescent Implantation Metastasis Model of Bladder Cancer and Real-time Microscopic Detection in Nude Mice. Asian Pac J Cancer Prev, 12:393–6.
Saokar A, Islam T, Jantsch M, et al., 2010, Detection of Lymph Nodes in Pelvic Malignancies with Computed Tomography and Magnetic Resonance Imaging. Clin Imaging, 34:361–6. DOI: 10.1016/j.clinimag.2009.07.004.
Cho EJ, Yang J, Mohamedali KA, et al., 2011, Sensitive Angiogenesis Imaging of Orthotopic Bladder Tumors in Mice Using a Selective Magnetic Resonance Imaging Contrast Agent Containing VEGF121/rGel. Invest Radiol, 46:441–9. DOI: 10.1097/rli.0b013e3182174fad.
Appel JH, Ren H, Sin ML, et al., 2016, Rapid Bladder Cancer Cell Detection from Clinical Urine Samples Using an Ultra-thin Silicone Membrane. Analyst, 141:652–60. DOI: 10.1039/c5an01616a.
Asanuma H, Arai T, Seguchi K, et al., 2003, Successful Diagnosis of Orthotopic Rat Superficial Bladder Tumor Model by Ultrathin Cystoscopy. J Urol, 169:718–20. DOI: 10.1097/00005392-200302000-00072.
Lee NP, Chan CM, Tung LN, et al., 2018, Tumor Xenograft Animal Models for Esophageal Squamous Cell Carcinoma. J Biomed Sci, 25:66. DOI: 10.1186/s12929-018-0468-7.
Day CP, Merlino G, Van Dyke T, 2015, Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges. Cell, 163:39–53. DOI: 10.1016/j.cell.2015.08.068.
Wege AK, 2018, Humanized Mouse Models for the Preclinical Assessment of Cancer Immunotherapy. BioDrugs, 32:245–66. DOI: 10.1007/s40259-018-0275-4.
Loukopoulos P, Kanetaka K, Takamura M, et al., 2004, Orthotopic Transplantation Models of Pancreatic Adenocarcinoma Derived from Cell Lines and Primary Tumors and Displaying Varying Metastatic Activity. Pancreas, 29:193–203. DOI: 10.1097/00006676-200410000-00004.
Lodillinsky C, Rodriguez V, Vauthay L, et al., 2009, Novel Invasive Orthotopic Bladder Cancer Model with High Cathepsin B Activity Resembling Human Bladder Cancer. J Urol, 182:749–55. DOI: 10.1016/j.juro.2009.03.076.
Lwin TM, Hoffman RM, Bouvet M, 2018, Advantages of Patient-derived Orthotopic Mouse Models and Genetic Reporters for Developing Fluorescence-guided Surgery. J Surg Oncol, 118:253–64. DOI: 10.1002/jso.25150.